000141325 001__ 141325
000141325 005__ 20240229121823.0
000141325 0247_ $$2doi$$a10.1002/jcsm.12335
000141325 0247_ $$2pmid$$apmid:30378296
000141325 0247_ $$2ISSN$$a2190-5991
000141325 0247_ $$2ISSN$$a2190-6009
000141325 0247_ $$2ISSN$$a=
000141325 0247_ $$2ISSN$$aJournal
000141325 0247_ $$2ISSN$$aof
000141325 0247_ $$2ISSN$$acachexia,
000141325 0247_ $$2ISSN$$asarcopenia
000141325 0247_ $$2ISSN$$aand
000141325 0247_ $$2ISSN$$amuscle
000141325 0247_ $$2ISSN$$a(Internet)
000141325 0247_ $$2altmetric$$aaltmetric:50577018
000141325 037__ $$aDKFZ-2018-01844
000141325 041__ $$aeng
000141325 082__ $$a610
000141325 1001_ $$aVeltkamp, Roland$$b0
000141325 245__ $$aExperimental ischaemic stroke induces transient cardiac atrophy and dysfunction.
000141325 260__ $$aHoboken, NJ$$bWiley$$c2019
000141325 3367_ $$2DRIVER$$aarticle
000141325 3367_ $$2DataCite$$aOutput Types/Journal article
000141325 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1555063080_4816
000141325 3367_ $$2BibTeX$$aARTICLE
000141325 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141325 3367_ $$00$$2EndNote$$aJournal Article
000141325 520__ $$aStroke can lead to cardiac dysfunction in patients, but the mechanisms underlying the interaction between the injured brain and the heart are poorly understood. The objective of the study is to investigate the effects of experimental murine stroke on cardiac function and molecular signalling in the heart.Mice were subjected to filament-induced left middle cerebral artery occlusion for 30 or 60 min or sham surgery and underwent repetitive micro-echocardiography. Left ventricular contractility was reduced early (24-72 h) but not late (2 months) after brain ischaemia. Cardiac dysfunction was accompanied by a release of high-sensitive cardiac troponin (hsTNT (ng/ml): d1: 7.0 ± 1.0 vs. 25.0 ± 3.2*; d3: 7.3 ± 1.1 vs. 52.2 ± 16.7*; d14: 5.7 ± 0.8 vs. 5.2 ± 0.3; sham vs. 60 min. MCAO; mean ± SEM; *p < 0.05); reduced heart weight (heart weight/tibia length ratio: d1: 6.9 ± 0.2 vs. 6.4 ± 0.1*; d3: 6.7 ± 0.2 vs. 5.8 ± 0.1*; d14: 6.7 ± 0.2 vs. 6.4 ± 03; sham vs. 60 min. MCAO; mean ± SEM; *p < 0.05); resulting from cardiomyocyte atrophy (cardiomyocyte size: d1: 12.8% ± 0.002**; d3: 13.5% ± 0.002**; 14d: 6.3% ± 0.003*; 60 min. MCAO vs. sham; mean ± SEM; **p < 0.01; *p < 0.05), accompanied by increased atrogin-1 and the E3 ubiquitin ligase murf-1. Net norepinephrine but not synthesis was increased, suggesting a reduced norepinephrine release or an increase of norepinephrine re-uptake, resulting in a functional denervation. Transcriptome analysis in cardiac tissue identified the transcription factor peroxisome proliferator-activated receptor gamma as a potential mediator of stroke-induced transcriptional dysregulation involved in cardiac atrophy.Stroke induces a complex molecular response in the heart muscle with immediate but transient cardiac atrophy and dysfunction.
000141325 536__ $$0G:(DE-HGF)POF3-322$$a322 - Genetics and Pathophysiology (POF3-322)$$cPOF3-322$$fPOF III$$x0
000141325 588__ $$aDataset connected to CrossRef, PubMed,
000141325 7001_ $$aUhlmann, Stefan$$b1
000141325 7001_ $$aMarinescu, Marilena$$b2
000141325 7001_ $$aSticht, Carsten$$b3
000141325 7001_ $$aFinke, Daniel$$b4
000141325 7001_ $$aGretz, Norbert$$b5
000141325 7001_ $$0P:(DE-HGF)0$$aGröne, Herrmann-Josef$$b6
000141325 7001_ $$aKatus, Hugo A$$b7
000141325 7001_ $$aBacks, Johannes$$b8
000141325 7001_ $$aLehmann, Lorenz H$$b9
000141325 773__ $$0PERI:(DE-600)2586864-0$$a10.1002/jcsm.12335$$n1$$p54-62$$tJournal of cachexia, sarcopenia and muscle$$v10$$x2190-5991$$y2019
000141325 909CO $$ooai:inrepo02.dkfz.de:141325$$pVDB
000141325 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000141325 9131_ $$0G:(DE-HGF)POF3-322$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vGenetics and Pathophysiology$$x0
000141325 9141_ $$y2019
000141325 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141325 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141325 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141325 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000141325 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000141325 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000141325 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ
000141325 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141325 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141325 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141325 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CACHEXIA SARCOPENI : 2017
000141325 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ CACHEXIA SARCOPENI : 2017
000141325 9201_ $$0I:(DE-He78)G130-20160331$$kG130$$lZelluläre und Molekulare Pathologie$$x0
000141325 980__ $$ajournal
000141325 980__ $$aVDB
000141325 980__ $$aI:(DE-He78)G130-20160331
000141325 980__ $$aUNRESTRICTED